My watch list  

49 Current news of Actelion


Jean-Pierre Garnier elected as Chairman of Actelion's Board of Directors


Actelion Ltd announced that Jean-Pierre Garnier has become Chairman of the Board of Directors of the Swiss biopharmaceutical company. The Board of Directors elected him at their meeting, 27 September 2011. In order to ensure a smooth transition, Robert Cawthorn, who has been Chairman since the ...


Actelion reports results of exploratory study with macitentan in IPF patients


Actelion announced that the exploratory Phase II study with macitentan in patients with idiopathic pulmonary fibrosis (IPF) shows a promising safety and tolerability profile of macitentan, no difference being observed between placebo and macitentan with regard to liver enzyme elevations. The ...


Actelion announces change in its Board of Directors


Actelion announced that Joseph C. Scodari - for personal reasons - has resigned from Actelion's Board of Directors at the beginning of August 2011.Robert Cawthorn, Chairman of the Board of Directors at Actelion, commented: "We would like to thank Joe for his dedication to Actelion. We have ...


Actelion's selective S1P1 receptor agonist ponesimod successful in mid-stage trial for multiple sclerosis

Ponesimod to proceed to Phase III final stage of clinical development


Actelion announced that the primary endpoint - reduction in the number of new active inflammatory lesions in the brain - has been met with its selective S1P1 receptor agonist, ponesimod, in a Phase IIb dose-finding study in patients with relapsing-remitting multiple sclerosis.The study assessed ...


Actelion announces change in its management structure

Otto Schwarz appointed Chief Operating Officer


Actelion Ltd announced that Otto Schwarz has been appointed Chief Operating Officer (COO). Otto Schwarz joined Actelion in 2008 as Head of Business Strategy & Operations. In addition to Commercial Operations and Business Strategy he assumes responsibility for Corporate Services, Global Quality ...


Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in patients with seasonal allergic rhinitis


Actelion Ltd announced that a Phase II study with its novel orally-active CRTH2 antagonist in seasonal allergic rhinitis has met its primary endpoint with statistical significance (pThe study assessed the efficacy and tolerability of various doses of this novel CRTH2 antagonist in adult patients ...


Jean-Pierre Garnier and Robert Bertolini nominated to join Actelion's Board


Actelion Ltd announced the nomination of Jean-Pierre Garnier and Robert Bertolini for election to the Company's Board of Directors at the 2011 Annual General Meeting (AGM) of shareholders, to be held on 05 May 2011. When elected, Jean-Pierre Garnier will become a Vice Chairman together with ...


Actelion awarded the Prix Hermès de l'Innovation


Actelion Ltd announced that the company will receive this year's Prix Hermès de l'Innovation in the category "amélioration de la condition humaine" (improvement in the conditions of human life).The European Institute for Creative Strategies and Innovation awards the Prix Hermès annually to ...


Actelion and GSK Discontinue Clinical Development of Almorexant


Actelion Ltd and GlaxoSmithKline announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the ...


Actelion announces change in its Board of Directors


Actelion Ltd announced that Dr. Elias Zerhouni has resigned from Actelion's Board of Director at the end of 2010. Dr. Zerhouni will focus on his new role as President, Global Research and Development at Sanofi-aventis, an executive function he is assuming as of the beginning of 2011. Robert ...


Page 2 From 5
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE